AI assistant
Clene Inc. — Director's Dealing 2021
Jan 4, 2021
34487_dirs_2021-01-04_67bcb4a7-68d9-48f7-b2ed-b46fbb9a4c4e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30
Reporting Person: Gay Jonathon (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 47962.00 | Direct |
| Common Stock | 1164749.00 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Incentive Stock Option (right to buy) | $0.53 | Common Stock (204895.00) | Direct |
Footnotes
F1: The securities are beneficially owned by KSV Gold, LLC. Mr. Gay is a member of KSV Gold, LLC's management team. The shares beneficially owned by KSV Gold, LLC. may also be deemed to be beneficially owned by Mr. Gay. However, Mr. Gay has no control over how the shares owned by KSV Gold, LLC are voted and disclaims all shares for which he does not have a pecuniary or profits interest.
F2: Awarded pursuant to that certain Non-Plan Stock Option Agreement, dated as of November 23, 2015, by and between Clene Nanomedicine, Inc. and the reporting person. The options are currently exercisable and expire 10 years from the date of the grant.